Commercial Times Highlights TCI’s Global Production Milestones and City Factory Strategy Set to Accelerate Growth

TCI Biotech (TCI Co., Ltd.), a leading liquid nutraceuticals innovator and global CDMO pioneer, was recently featured in a prominent report by the Commercial Times. The deep-dive coverage spotlighted the company’s resilient global restructuring, technological breakthroughs, and advanced City Factory localization strategy.

The feature detailed how TCI has successfully navigated past pandemic disruptions and global supply chain re-alignment by optimizing its international manufacturing footprints. A key pillar of this strategy is the massive upgrade to TCI’s Utah facility in the United States, transitioning from a rental model to full ownership. This move firmly establishes TCI’s ability to provide “Made in USA” liquid nutrition and functional supplements natively to major North American retail and direct-selling clients.

A Deep Commitment to Green Manufacturing and ESG Leadership

The article highlighted TCI’s proactive City Factory framework, championed by Chairman Vincent Lin. By embedding highly automated, agile production lines close to core metropolitan markets, TCI has drastically shortened delivery lead times, circumvented global tariff uncertainties, and built deep supply elasticity. This model has already rolled out successfully across key hubs, with upcoming expansions targeting major economic centers like Tokyo.

Beyond localized infrastructure, TCI’s high-margin technological innovations are creating massive competitive moats:

• Next-Gen doubleNUTRI® ZerO₂™ (DNZ) Liquid Sachets: As a leading liquid nutraceuticals innovator, TCI developed this proprietary deoxygenation and liposomal encapsulation technology to guarantee a 730-day active ingredient shelf-life, solving a historic degradation pain point for global liquid supplement brands.

• Global Client Success: TCI has successfully integrated into the supply chains of over a dozen international consumer brands boasting annual revenues exceeding US$1 billion, with several partnerships expanding from regional agreements into comprehensive global contracts.

As manufacturing and automation alignments finalize, market analysts and institutional reports project a highly positive trajectory for TCI throughout the coming quarters, positioning the company to challenge historic revenue peaks.

Originally reported by the Commercial Times. Click here to view the original media report.